Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock

Benjamin Hibbert, MD, PhD, addresses the need for randomized clinical trials to fill evidence gaps in cardiovascular care. Dr. Hibbert's group completed the DoReMi Study, an RCT comparing the use of dobutamine versus milrinone in cardiogenic shock, and has similarly themed studies underway.
[5:58] Cardiogenic shock
[8:59] Resident and fellow led research
[11:19] DOREMI trial
[23:26] Future directions
Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock
www.nejm.org/doi/full/10.1056...
Follow the Yale Heart Failure program on Twitter.
/ yalehf